Ischemia Reperfusion Injury - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 35 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.
Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)
Reasons to buy- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Introduction
- Global Markets Direct Report Coverage
- Ischemia Reperfusion Injury - Overview
- Ischemia Reperfusion Injury - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ischemia Reperfusion Injury - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
- Akashi Therapeutics Inc
- Argenx SE
- Balmes Transplantation SAS
- Bolder Biotechnology Inc
- Catalyst Biosciences Inc
- Celdara Medical LLC
- Cellmid Ltd
- CFM Pharma Holding BV
- Corline Biomedical AB
- Cypralis Ltd
- Gilead Sciences Inc
- Glucox Biotech AB
- Ischemix Inc
- Lee's Pharmaceutical Holdings Ltd
- LG Chem Ltd
- Mallinckrodt Plc
- Orion Corp
- Pfizer Inc
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- SBI Pharmaceuticals Co Ltd
- Stealth BioTherapeutics Corp
- United Therapeutics Corp
- Ischemia Reperfusion Injury - Drug Profiles
- aminolevulinic acid hydrochloride - Drug Profile
- ANV-6L15 - Drug Profile
- AP-39 - Drug Profile
- APP-103 - Drug Profile
- ARGX-117 - Drug Profile
- AT-300 - Drug Profile
- BBT-059 - Drug Profile
- BT-0213 - Drug Profile
- BT-0301 - Drug Profile
- BT-0402 - Drug Profile
- CAB-101 - Drug Profile
- cannabidiol - Drug Profile
- CB-2782 - Drug Profile
- CC-4066 - Drug Profile
- cerium oxide - Drug Profile
- CMX-2043 - Drug Profile
- cyclocreatine phosphate - Drug Profile
- Cymac-001 - Drug Profile
- DH-404 - Drug Profile
- Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis - Drug Profile
- IL-233 - Drug Profile
- KN-93 - Drug Profile
- LC-280126 - Drug Profile
- MG-53 - Drug Profile
- Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock - Drug Profile
- Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile
- MP-3964 - Drug Profile
- NLS-3 - Drug Profile
- NP-202 - Drug Profile
- Oligonucleotide for Cardiovascular Diseases and Oncology - Drug Profile
- ORM-10103 - Drug Profile
- PEG-HCC - Drug Profile
- Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile
- R-100 - Drug Profile
- R-190 - Drug Profile
- Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders - Drug Profile
- Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile
- Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
- Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
- Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile
- regadenoson - Drug Profile
- Remodulin - Drug Profile
- Renaparin - Drug Profile
- SBT-20 - Drug Profile
- SBT-272 - Drug Profile
- sirolimus - Drug Profile
- Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury - Drug Profile
- Small Molecules for Ischemia Reperfusion Injury - Drug Profile
- Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation - Drug Profile
- Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury - Drug Profile
- Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile
- Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile
- Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury - Drug Profile
- Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
- Synthetic Peptide for Ischemia Reperfusion Injury - Drug Profile
- Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology - Drug Profile
- Ti-061 - Drug Profile
- tiomolibdate diammonium - Drug Profile
- tiprelestat - Drug Profile
- tofacitinib citrate - Drug Profile
- UWA-TAT - Drug Profile
- Vanadis-01 - Drug Profile
- Vanadis-03 - Drug Profile
- VCP-746 - Drug Profile
- YQ-23 - Drug Profile
- ZK-001 - Drug Profile
- Ischemia Reperfusion Injury - Dormant Projects
- Ischemia Reperfusion Injury - Discontinued Products
- Ischemia Reperfusion Injury - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Ischemia Reperfusion Injury, H2 2019
- Number of Products under Development by Companies, H2 2019
- Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
- Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
- Number of Products under Development by Universities/Institutes, H2 2019
- Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019 (Contd..1), H2 2019
- Products under Development by Companies, H2 2019 (Contd..2), H2 2019
- Products under Development by Universities/Institutes, H2 2019
- Number of Products by Stage and Target, H2 2019
- Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
- Number of Products by Stage and Mechanism of Action, H2 2019
- Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
- Number of Products by Stage and Route of Administration, H2 2019
- Number of Products by Stage and Molecule Type, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Akashi Therapeutics Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Argenx SE, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Catalyst Biosciences Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Cellmid Ltd, H2 2019
- Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2019
- Ischemia Reperfusion Injury - Pipeline by LG Chem Ltd, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Orion Corp, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H2 2019
- Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2019
- Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, H2 2019
- Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, H2 2019
- Ischemia Reperfusion Injury - Dormant Projects, H2 2019
- Ischemia Reperfusion Injury - Discontinued Products, H2 2019
- List of Figures
- Number of Products under Development for Ischemia Reperfusion Injury, H2 2019
- Number of Products under Development by Companies, H2 2019
- Number of Products under Development by Universities/Institutes, H2 2019
- Number of Products by Top 10 Targets, H2 2019
- Number of Products by Stage and Top 10 Targets, H2 2019
- Number of Products by Top 10 Mechanism of Actions, H2 2019
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
- Number of Products by Routes of Administration, H2 2019
- Number of Products by Stage and Routes of Administration, H2 2019
- Number of Products by Molecule Types, H2 2019
- Number of Products by Stage and Molecule Types, H2 2019